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Abstract
Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic condition most commonly
characterized by hypertrophy of the ventricular septum, which leads to left ventricle outflow
obstruction. Due to the severity of the condition, it is often diagnosed in adolescents, especially
in those who exercise. We describe the case of a 53-year-old male, previously undiagnosed with
hypertrophic cardiomyopathy (HCM), who became dyspneic during a bike race. He was found to
have elevated troponin, pulmonary edema, and was diagnosed with HOCM. The late
presentation of the case, in an active individual, makes the situation unique.
Categories: Cardiology, Emergency Medicine, Family/General Practice
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Introduction
Hypertrophic cardiomyopathy (HCM) is a relatively common genetic condition. It is a result of
one or more missense mutations in genes encoding proteins of the cardiac sarcomere [1]. The
condition affects 1 in 500 in the general population, disproportionately affecting athletes [2-3].
It is most commonly characterized by hypertrophy of the ventricular septum, though there are
other less common types [4]. In 20% to 25% of patients, left ventricular (LV) outflow obstruction
may occur, which is caused by impingement of the mitral valve leaflets on the hypertrophied
basal septum and a pressure gradient that pulls the mitral valve anteriorly [3,5]. Depending on
the severity of the condition, patients may be asymptomatic, though end-stage patients may
present with symptoms mirroring a heart attack, systolic dysfunction, ventricular arrhythmias,
valvular stenosis, and sudden death [2,6]. Due to the severity of the condition, it most
commonly becomes apparent during puberty, when growth spurts occur [1].
Case Presentation
Our patient was a 53-year-old man participating in a day-long bike race. His past medical
history was limited to hypertension, and controlled with amlodipine. During the race, he was
severely short of breath and presented to the medical tent. He noted some subjective
improvement with a single dose of 2.5 mg albuterol but his shortness of breath persisted
triggering his visit to a critical access emergency room (ER). He did not experience any
associated pain.
In the ER, he was noted to have multiple electrocardiogram (EKG) abnormalities and
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a referral center ER. His EKG showed left atrial enlargement and a hyperdynamic QRS wave
without evidence of acute myocardial infarction (Figure 1). He continued to experience
shortness of breath and hypoxemia to 88% O2 on room air, and became tachypneic. He
responded well to 4L nasal cannula with O2 saturation on pulse oximetry of 96%. Additionally,
vital signs were a temperature of 98.8, blood pressure of 155/85, heart rate of 88, and
respiratory rate of 22 that resolved to 16 with initial therapy. Computed tomography (CT) of
the chest revealed pulmonary edema without evidence of pulmonary embolism (Figure 2). Lab
results revealed a troponin I of 0.29 ng/mL, a brain natriuretic peptide (BNP) of 199 pg/mL, and
leukocytosis of 23.3 K/uL. Otherwise, his complete metabolic panel, urine drug screen, and
lactate were unremarkable.
FIGURE 1: Electrocardiogram (EKG) displaying hyperdynamic
QRS waves
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FIGURE 2: Computed tomography (CT) of the chest (coronal
view) showing pulmonary edema
During the remainder of his ER course, he did not require further respiratory intervention. He
was given a dose of 40 mg intravenous (IV) Lasix for pulmonary edema and gradually improved
as a result. He was admitted to the inpatient unit where an echocardiogram revealed severe
asymmetric septal-hypertrophy and hypertrophic obstructive physiology with left ventricular
outflow tract (LVOT) resting pressure gradient of 31 mmHg, mild left atrial-chamber
enlargement, and moderate mitral valve regurgitation, but no left ventricle wall motion
abnormality (Figures 3-5). Percutaneous coronary angiography revealed mild-diffuse luminal
irregularities of the left main coronary artery, first diagonal branch, third obtuse marginal
branch, and right coronary artery (which was dominant).
FIGURE 3: Parasternal long axis with arrow pointing to
hypertrophic septum
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FIGURE 4: Apical four-chamber view with arrow pointing to
hypertrophied septum
2019 Minckler et al. Cureus 11(6): e4875. DOI 10.7759/cureus.4875 4 of 7
FIGURE 5: Subxiphoid window with white arrow pointing to
hypertrophied septum and red arrow pointing to hypertrophied
left ventricular wall
He was placed on long-acting diltiazem and amlodipine was discontinued. Additionally, he was
started on low dose aspirin with dietary risk factor modification, daily atorvastatin, good oral
hydration, and a low sodium diet. Cardiology follow up was established and the remainder of
his hospital course was uncomplicated with a continued resolution of presenting symptoms.
Discussion
We are taught that hypertrophic obstructive cardiomyopathy (HOCM) is present in young
athletes. The initial presentation of HOCM in an athlete over the age of 50 makes this case
unique. When a person over the age of 50 presents to the ER with acute shortness of breath and
elevated troponin, previously undiagnosed decompensated HOCM is very low on the
differential, if it is even considered.
The first important learning point, in this case, is to identify the cognitive bias associated with
the idea that HOCM is a disease of adolescents. This bias had been propagated through our
training as the majority of HOCM diagnosis are made in young athletes. Though this case is
relatively rare, we must recognize that HOCM is not a disease exclusively confined to
adolescents, given the estimated genetic preponderance of 1 in 500 people having some form of
this disease. The burden of previously undiagnosed individuals with subclinical disease is likely
encountered much more than providers anticipate in primary care and emergency medicine.
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When we think of the initial presentation of HOCM, our interest is piqued when a patient
describes a syncopal event during exercise. However, that is the textbook presentation of an
undiagnosed adolescent. In this case, the patient’s initial presentation was dyspnea due to
pulmonary edema and elevated troponin. This closely mimicked the presentation of acute
decompensated congestive heart failure (CHF). Except, the patient’s blood pressure was not
grossly elevated, it was 155 systolic/82 diastolic and his BNP was only 199, which is not
consistent with severe CHF.
People with HOCM do suffer from varying degrees of coronary microvascular dysfunction,
given the myocardial fiber disarray inherent in this disease [7-8]. Superimposed atherosclerotic
coronary artery disease (CAD) further limits myocardial perfusion capabilities in these at-risk
hearts [9]. Therefore, mild diffuse CAD that would otherwise be asymptomatic in a normal heart
may precipitate acute decompensation in an older athlete with HOCM.
Conclusions
In conclusion, the burden of HOCM in the population is larger than most providers see in
practice with many cases likely being subclinical. Lacking a previous diagnosis of HOCM does
not exclude an adult athlete from having this disease since a first decompensation event can
have a temporal pattern not regularly taught in training, though this is uncommon. A first
decompensation event in an adult athlete may have a clinical presentation that mimics other
acute chest pathophysiology and may not fit the text-book presentation of this disease, though
further research will be necessary to elucidate this.
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